Home Companies Catalysts Deep Dives
Calquence acalabrutinib APPROVED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaOncology
Launch2017-10-31
US LOE2036-07-01
Peak Sales Est$4000M
Formulations[{"id":"calquence-oral","doses":"100mg capsules","route":"Oral","setting":"PATIENT_SELF","frequency"
Companies
AZN (ORIGINATOR)100%
ACERTA (ORIGINATOR)0%
Mechanism: BTK inhibitor
Expert: Selective covalent inhibitor of Bruton's tyrosine kinase that disrupts B-cell receptor signaling critical for CLL and MCL survival.
Everyday: Blocks a protein that B-cell cancers need to survive and grow.
Targets: ["BTK"]
Revenue History
PeriodRevenue ($M)
2023$2,531M
2024$2,892M
Q1 2025$780M
Q2 2025$820M
Programs (2)
IndicationStageKey StudyRegional Status
MCLAPPROVEDACE-LY-004[{"stage":"APPROVED","region":"US","approval_date":"2017-10-31"},{"stage":"APPRO
CLLAPPROVEDELEVATE-TN[{"stage":"APPROVED","region":"US","approval_date":"2019-11-21"},{"stage":"APPRO
Notes
BTK inhibitor for CLL.
Data from Supabase · Updated 2026-03-24